$SNOA News

Last published 1d ago

1d agoSNOASonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income TaxACCESS NewswireSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced financial results for its second fiscal quarter ended September 30, 2026. "We ar ...
3mo agoSNOASonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDAACCESS NewswireTotal revenue increased 60% year over year to $6.4 millionNet loss per share decreased 88% compared to the prior-year quarterGross margin expanded to 40% as operating expenses remained stableFDA clearance and new global
4mo agoSNOASonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation SolutionACCESS NewswireBOULDER, CO / ACCESS Newswire / June 30, 2026 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader in hypochlorous acid technology, today announced it has received a new 510 clearance from
4mo agoSNOASonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial ResultsACCESS NewswireRevenues increased 48% in Q4 2026 compared to Q4 2025, and 37% in FY 2026 compared to FY 2025United States revenues increased 194% in Q4 2026 compared to Q4 2025 and 117% in FY 2026 compared to FY 2025Net loss improved
6mo agoSNOASonoma Pharmaceuticals Announces Pricing of $4 Million Public OfferingACCESS NewswireBOULDER, CO / ACCESS Newswire / April 24, 2026 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader in hypochlorous acid technology, today announced
7mo agoSNOASonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and WalmartACCESS NewswireBOULDER, CO / ACCESS Newswire / March 24, 2026 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader in hypochlorous acid technology, today announced the U.S. retail launch of its advanced
7mo agoSNOASonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive SkinACCESS NewswireBOULDER, CO / ACCESS Newswire / March 18, 2026 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
9mo agoSNOASonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial ResultsACCESS NewswireRevenue increased 22% for the quarter ended December 31, 2025 and 33% for the nine months ended December 31, 2025 compared to prior yearNet loss and net loss per share decreased from prior year for both the three months
9mo agoRNA SNOASonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product DevelopmentACCESS NewswireBOULDER, CO / ACCESS Newswire / January 28, 2026 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
12mo agoSNOANational Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn AdvancedACCESS NewswireBOULDER, CO / ACCESS Newswire / November 13, 2025 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
1y agoSNOASonoma Pharmaceuticals to Exhibit at MEDICA 2025 in DüsseldorfACCESS NewswireBOULDER, CO / ACCESS Newswire / November 6, 2025 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid
1y agoSNOASonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial ResultsACCESS NewswireRevenues increased 57% for the quarter and 38% for the six months ended September 30, 2025 compared to same periods last yearU.S. revenue increased 115% for the quarter and 86% for the six months ended September 30, 2025
1y agoSNOASonoma Pharmaceuticals and Medline Industries Launch New HOCl Wound Cleanser for U.S. HospitalsACCESS NewswireBOULDER, CO, AL / ACCESS Newswire / October 14, 2025 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader in developing and producing stabilized hypochlorous acid products based on its patented
1y agoSNOASonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRAACCESS NewswireBOULDER, COLORADO / ACCESS Newswire / October 7, 2025 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous
1y agoSNOASonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025ACCESS NewswireBOULDER, COLORADO / ACCESS Newswire / September 25, 2025 / Sonoma Pharmaceuticals, Inc.
1y agoSNOANational Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn AdvancedACCESS NewswireBOULDER, CO / ACCESS Newswire / August 26, 2025 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
1y agoSNOASonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. ChainsACCESS NewswireBOULDER, CO / ACCESS Newswire / August 13, 2025 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
1y agoSNOASonoma Pharmaceuticals Reports First Fiscal Quarter 2026 Financial ResultsACCESS NewswireRevenues increased 18% compared to same period last yearU.S. revenue increased 57% compared to same period last yearNet loss per share decreased 43% compared to same period last year BOULDER, COLORADO / ACCESS Newswire /
1y agoSNOASonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial ResultsACCESS NewswireRevenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss improved 59% in Q4 2025
1y agoSNOASonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy ChainACCESS NewswireBOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
1y agoSNOASonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)ACCESS NewswireBOULDER, CO / ACCESS Newswire / March 10, 2025 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
1y agoSNOASonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in OrlandoACCESS NewswireBOULDER, CO / ACCESS Newswire / February 25, 2025 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
1y agoSNOASonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial ResultsACCESS NewswireRevenues increased 14% for the quarter compared to prior year and 13% year-to-datePositive cash flow from operations for the quarter with $5.2 million of cash at December 31, 2024Year-to-date net loss decline of $1.1
1y agoSNOASonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical DevicesACCESS NewswireBOULDER, CO / ACCESSWIRE / December 5, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
1y agoSNOASonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United StatesACCESS NewswireBOULDER, CO / ACCESSWIRE / November 21, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care HydrogelACCESS NewswireBOULDER, CO / ACCESSWIRE / November 11, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial ResultsACCESS NewswireRevenue increased 31% for the quarter compared to same period prior yearPositive cash flows from operations of $0.35 million for the quarterNet loss improved 59% for the quarter compared to same period prior yearNet loss
2y agoSNOASonoma Pharmaceuticals to Exhibit at MEDICA 2024 in DüsseldorfACCESS NewswireBOULDER, CO / ACCESSWIRE / October 31, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in CanadaACCESS NewswireBOULDER, CO / ACCESSWIRE / October 22, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor ConferencesACCESS NewswireBOULDER, CO / ACCESSWIRE / October 21, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleACCESS NewswireBOULDER, CO / ACCESSWIRE / September 19, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based SolutionACCESS NewswireBOULDER, CO / ACCESSWIRE / September 17, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product LineACCESS NewswireBOULDER, CO / ACCESSWIRE / September 11, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common StockACCESS NewswireBOULDER, CO / ACCESSWIRE / August 28, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-DiffACCESS NewswireBOULDER, CO / ACCESSWIRE / August 26, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United StatesACCESS NewswireBOULDER, CO / ACCESSWIRE / August 21, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals Reports First Fiscal Quarter 2025 Financial ResultsACCESS NewswireEuropean revenues increased 20% compared to same period last yearGross margin of 39% compared to 35% in same period last yearNet loss improved 19% compared to same period last year BOULDER, CO / ACCESSWIRE / August 8,
2y agoSNOASonoma Pharmaceuticals Celebrates 20 Years of Selling Wound Care Products in Europe and Announces New Distributor in UkraineACCESS NewswireBOULDER, CO / ACCESSWIRE / July 9, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial ResultsACCESS NewswireRevenues increased 14% in Q4 2024 compared to Q4 2023Gross profit margin improved 3% in FY 2024 compared to FY 2023Net loss improved 18% in Q4 2024 compared to Q4 2023, and 6% in FY 2024 compared to FY 2023BOULDER, CO /
2y agoSNOASonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement StoresACCESS NewswireBOULDER, CO / ACCESSWIRE / May 9, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United StatesACCESS NewswireBOULDER, CO / ACCESSWIRE / April 9, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract InfectionsACCESS NewswireBOULDER, CO / ACCESSWIRE / April 4, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor ConferencesACCESS NewswireBOULDER, CO / ACCESSWIRE / March 28, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other TopicalsACCESS NewswireBOULDER, CO / ACCESSWIRE / March 27, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoSNOASonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial ResultsACCESS NewswireRevenues increased 7% compared to quarter from prior year and 15% from prior quarterImprovement in gross margin for quarter of 19% compared to prior yearImprovement in net loss for quarter of $1.0 million compared to
2y agoSNOASonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily UseACCESS NewswireBOULDER, CO / ACCESSWIRE / January 23, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
2y agoNBY SNOANovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma's Extensive Distributor NetworkBusiness WireNovaBay Pharmaceuticals, Inc. (NYSE:NBY) and Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced an agreement for the sale and marketing of Avenova®-branded products by Sonoma in the European Union. The new
2y agoNBY SNOANovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma's Extensive Distributor NetworkACCESS NewswireEMERYVILLE, CA and BOULDER, CO / ACCESSWIRE / January 9, 2024 / NovaBay Pharmaceuticals, Inc. and Sonoma Pharmaceuticals, Inc. today announced an agreement for the sale and marketing of
2y agoSNOASonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial ResultsACCESS NewswireGross profit percentage of 36% for the quarter, up 1% from first fiscal quarter 2024Total operating expenses decreased for the quarter and six months ended September 30, 2023 compared to same period prior yearEuropean
3y agoSNOASonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall ConferenceACCESS NewswireBOULDER, CO / ACCESSWIRE / November 3, 2023 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid